MANTA Brings Glimmer Of Good News To Galapagos
Promising Early Filgotinib Data Boosts Stock
After a difficult spell for the Belgian biotech, positive interim data from two key studies looking at testicular toxicity concerns over filgotinib suggest a pathway for potential future US approval of the Gilead-partnered JAK inhibitor for IBD.